Abstract
Intercellular adhesion molecule-1 (ICAM-1) expression correlates with tumour progression in patients with malignant melanoma or renal cell carcinoma. To assess the value of soluble ICAM-1 (sICAM-1) for lung cancer patients, sICAM-1 was determined by means of an enzyme-linked immunosorbent assay. Sera from 147 patients with lung cancer, from 75 patients with benign lung diseases and from 108 healthy adults were investigated for sICAM-1 expression. Significant differences in sICAM-1 levels were detected in lung cancer patients (387 ± 176 ng/ml) and patients with benign lung diseases (365 ± 110 ng/ml) compared to the group of healthy adults (310 ± 90 ng/ml). There was no difference in sICAM-1 level among the subtypes of lung cancer. Advanced tumour stages and patients with progressive disease tended to be associated with higher sICAM-1 levels, the site of metastasis being relevant for the level attained. Patients with liver metastasis had the highest sICAM-1 levels (547 ± 295 ng/ml) compared to patients with cerebral metastasis (317.8 ± 92.2 ng/ml). An increase of sICAM-1 expression during the progression of the disease coincided with a poorer survival prognosis for the patients compared to patients with stable or falling sICAM-1 levels.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 5 January 1997 / Accepted: 12 August 1997
Rights and permissions
About this article
Cite this article
Sprenger, A., Schardt, C., Rotsch, M. et al. Soluble intercellular adhesion molecule-1 in patients with lung cancer and benign lung diseases. J Cancer Res Clin Oncol 123, 632–638 (1997). https://doi.org/10.1007/s004320050117
Issue Date:
DOI: https://doi.org/10.1007/s004320050117